151: Immunotherapy immediately following transplantation for multiple myeloma
نویسندگان
چکیده
منابع مشابه
Immunotherapy for Multiple Myeloma
1Clinic for Stem Cell Transplantation, Center of Oncology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany 2 Service d’Hématologie Clinique, Hôpital Hôtel-Dieu, CHU de Nantes, Place Alexis Ricordeau, 44093 Nantes Cedex, France 3Hematology and Bone Marrow Transplantation, Internal Medicine, Chaim Sheba Medical Center, 52621 Tel-Hashomer, Israel 4Department o...
متن کاملImmunotherapy in Multiple Myeloma
The treatment of multiple myeloma has evolved significantly over the past decades, spanning from alkylator-based therapy to the more recent novel therapies that include proteasome inhibition and immunomodulatory agents. The introduction of immunotherapy to the treatment landscape of multiple myeloma has led to the development of new strategies and therapies that engage the immune system to enha...
متن کاملAutologous transplantation for multiple myeloma.
Until now high-dose therapy (HDT) supported by autologous stem cell transplantation (ASCT) has been considered the standard of care for frontline therapy of multiple myeloma (MM) in younger patients with normal renal function, and MM is currently the first indication of ASCT. However, the introduction of the novel agents thalidomide, bortezomib and lenalidomide is changing the scenario in two w...
متن کاملImmunotherapy Strategies Against Multiple Myeloma
Multiple myeloma is a monoclonal B-cell malignancy characterized by an accumulation of malignant plasma cells in the bone marrow, the presence of a monoclonal protein in the serum and/or urine, decreased normal immunoglobulin levels, and lytic bone disease. Patients with multiple myeloma benefit from combination therapy including novel therapeutic agents followed by autologous stem cell transpl...
متن کاملMULTIPLE MYELOMA Stem cell transplantation in multiple myeloma
High-dose treatment (HDT) with autologous stem cell transplantation (ASCT) has been shown to increase survival and time to progression in multiple myeloma (IMM) compared with conventional chemotherapy. In the French IFM90-study [1], 200 patients were randomised to receive prolonged standard treatment with i.v. combination chemotherapy, or a short phase by induction treatment with the same regim...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Biology of Blood and Marrow Transplantation
سال: 2007
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2006.12.155